<DOC>
	<DOCNO>NCT00395213</DOCNO>
	<brief_summary>This study evaluate risk benefit treatment selective serotonin reuptake inhibitor serotonin-norepinephrine reuptake inhibitor child adolescents pre-specified anxiety disorder , depressive disorder , eat disorder , obsessive-compulsive disorder .</brief_summary>
	<brief_title>Antidepressant Safety Kids Study</brief_title>
	<detailed_description>The Antidepressant Safety Kids ( ASK ) study part Child Adolescent Psychiatry Trials Network ( CAPTN ) . Selective serotonin reuptake inhibitor ( SSRI ) serotonin-norepinephrine reuptake inhibitor ( SNRI ) medication prescribe approximately 2 3 % American child . Evidence suggest medication beneficial treat obsessive-compulsive disorder ( OCD ) , anxiety disorder , major depressive disorder . Following hearing February September 2004 , FDA mandate Black Box warn antidepressant , caution prescribers risk treatment-emergent suicidal tendency child adolescent treat drug . Although prescribe wan somewhat follow warn , many child continue receive SSRIs SNRIs variety condition empirically validate alternative treatment . Therefore , press need clearly understand safety , tolerability , effectiveness SSRIs SNRIs child adolescent . Specific Aim : The purpose study evaluate safety , tolerability , effectiveness SSRI SNRI medication child adolescent anxiety disorder , depressive disorder , eat disorder , obsessive-compulsive disorder . The study characterize predictor outcome , include demographic , disease severity , comorbidity , concomitant treatment , genetic variation . This information help clinicians good understand balance risk benefit associate antidepressant answer question treatment best child . Three specific aim include follow : 1 . To evaluate within-subject benefit antidepressant treatment acute ( 12 week ) maintenance ( additional 6 month ) treatment ; 2 . To evaluate adverse event profile harm self , harm others , psychiatric nonpsychiatric adverse event ; 3 . To evaluate potential moderator mediator benefit adverse event . Design : This prospective longitudinal cohort study 2,420 consecutively enrolled patient prescribe SSRI SNRI ( Citalopram [ Celexa ] , Escitalopram [ Lexapro ] , Fluoxetine [ Prozac/Prozac Weekly ] , Fluvoxamine [ Luvox ] , Paroxetine , [ Paxil/Paxil-Cr ] , Sertraline [ Zoloft ] , Venlafaxine [ Effexor/Effexor XR ] , Duloxetine [ Cymbalta ] ) . Patients drawn practice approximately 200 CAPTN participant United States Canada . Study Timeline : This study two phase : 1 ) acute treatment phase follow initiation treatment SSRI SNRI clinician 's choose 2 ) long-term follow-up phase . The acute treatment phase last 12 week long-term follow-up phase occur 6 9 month initiation treatment . Treatment : Flexible upward titration commercially available SSRI SNRI medication . As decided treating doctor , titration depend severity illness , degree response , adverse event profile . With exception , concomitant treatment permit . Assessment : Study assessment milestone occur baseline , Week 12 , Months 6 9 study entry . CAPTN use `` query rule '' electronic data capture system . The parent child complete pen paper workbook consist primarily DISC Predictive Scales ( DPS-IV ) Pediatric Adverse Event Rating Scale ( PAERS ) . Based information clinical interview , treat clinician complete fully web-based EDC module baseline treatment end-of-study visit .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Receiving treatment outpatient , residential , inpatient set Meets DSMIV diagnostic criterion least one follow disorder : anxiety disorder , depressive disorder , eat disorder , obsessivecompulsive disorder English Spanishspeaking Inpatient status IF enrolling inpatient clinician continue follow patient duration study Sibling already enrol study Imminently suicidal unable comply nosuicide contract , opinion treat clinician , inadequate family monitoring suicidality Acutely psychotic study entry A demonstrated lack benefit intolerance SSRI/SNRI antidepressant , class Receiving treatment tricyclic antidepressant ( TCA ) study enrollment , exception low dos enuresis chronic pain . Patients may receive adjunctive TCA treatment study clinician 's discretion . Received monoamine oxidase inhibitor ( MAOI ) , isocarboxazid ( Marplan ) , phenelzine ( Nardil ) , tranylcypromine ( Parnate ) , within past 30 day Parasuicidal behavior milder form suicidality activation meet diagnostic criterion Refusal participate pharmacogenomic study For bipolar depress patient , mixed manicstate study entry without stable treatment mood stabilizer manic symptom Patient family unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>Major Depression</keyword>
	<keyword>Anorexia</keyword>
	<keyword>Bulimia</keyword>
	<keyword>OCD</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>SSRI</keyword>
	<keyword>SNRI</keyword>
</DOC>